InVivo Therapeutics to Present at 15 th Annual Rodman and Renshaw Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and neurotrauma conditions, today announced that Acting Chief Financial Officer Sean Moran is scheduled to present to investors at the 15th Annual Rodman and Renshaw Healthcare Conference to be held September 8-10, 2013 at the Millennium Broadway Hotel in New York City. The presentation is scheduled for Tuesday, September 10 at 2:25 pm ET in Room 704 on the 7th Floor. A live webcast will be available at http://wsw.com/webcast/rrshq23/NVIV.
Additional information about the 15th Annual Rodman and Renshaw Healthcare Conference can be found at http://www.rodm.com/conferences.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is focused on utilizing polymers as a platform technology to develop treatments for serious diseases and conditions, including improving function in individuals paralyzed as a result of traumatic spinal cord injury. The Company was founded in 2005 on the basis of proprietary technology co-invented by Robert Langer, ScD., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011, the Company earned the prestigious David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties, and include statements regarding the Company's expectations with respect to the commencement of human clinical trials, the length of time to complete human clinical trials and conducting additional studies. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Institutional Review Board process, the Company's ability to obtain FDA approval to commercialize its products, the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in our filings with the SEC, including our Form 10-K and 10-Q's and our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.
InVivo Therapeutics Holdings Corp.
Brian Luque, 617-863-5535
Director, Investor Relations
KEYWORDS: United States North America Massachusetts
The article InVivo Therapeutics to Present at 15th Annual Rodman and Renshaw Healthcare Conference originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.